Modeling multi-drug chemotherapy: tailoring treatment to individuals.

BACKGROUND Predicting and tailoring optimal cancer treatments presents a major challenge. METHODS A computational model (kinetically tailored treatment, or KITT model) is developed to predict drug combinations, doses, and schedules likely to be effective in reducing tumor size and prolonging patient life. Treatment strategies may be tailored to individuals based on tumor cell kinetics. The model incorporates intra-tumor heterogeneity and evolution of drug resistance, apoptotic rates, and cell division rates. Tumor growth may follow an exponential or a Gompertzian trajectory. Drug pharmacodynamic and pharmacokinetic models are used. Toxicity is modeled in several ways. RESULTS A key prediction of KITT is that including cytostatic drugs like tamoxifen and herceptin during treatment with cytotoxic drugs substantially increases the probability of cure and prolongs patient life. Results also suggest that altering drug scheduling may be more effective but not more toxic than dose escalation. CAF chemotherapy (cyclophosphamide, adriamycin, and 5-fluorouracil) is predicted to be more effective than CMF (cyclophosphamide, methotrexate, and 5-fluorouracil). KITT also suggests that tumors with a high proliferative index (PI) may respond better to drug combinations incorporating two cell-cycle phase-specific drugs than do tumors with a low PI. Tumors with a low PI, in contrast, are predicted to respond better to regimens involving two cell-cycle phase-non-specific drugs than do tumors with a high PI. These predictions are borne out by clinical trial results published in the literature, which are discussed. Simulated predictions of the model match well with results from a clinical trial by Silvestrini et al. (2000. Int. J. Cancer 87, 405). The results of simulating the growth of 26896 tumors are used to construct a decision tree for prognosis to identify the key tumor and treatment variables. CONCLUSION Additional tests of the model are needed in which physicians collect information on apoptotic and proliferative indices, cell-cycle times, and drug resistance from biopsies of each individual's tumor. Computational models may become important tools to help optimize and tailor cancer treatments.

[1]  D. Lacombe,et al.  Phase I/II trial of continuous infusion vinorelbine for advanced breast cancer. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  G. Bonadonna,et al.  Cell proliferation and outcome following doxorubicin plus CMF regimens in node‐positive breast cancer , 2000 .

[3]  Xin Xie,et al.  The prognostic value of spontaneous apoptosis, Bax, Bcl‐2, and p53 in oral squamous cell carcinoma of the tongue , 1999, Cancer.

[4]  G. Mathé The kinetics of cancer cells and of HIV1: the problems of cell and virus rebounds and of latency. , 1998, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[5]  A. D. Schryver,et al.  Systemic treatment of early breast-cancer by hormonal, cytotoxic, or immune therapy: 133 randomized trials involving 31000 recurrences and 24000 deaths among 75000 women: 1 , 1992 .

[6]  R. Hoffman,et al.  Hematology: Basic Principles and Practice , 1995 .

[7]  R. Souhami Will increases in dose intensity improve outcome: con. , 1995, The American journal of medicine.

[8]  P. Vaupel,et al.  Hypoxic cervical cancers with low apoptotic index are highly aggressive. , 1999, Cancer research.

[9]  G. Bonadonna,et al.  Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results. , 1995, JAMA.

[10]  F. Landoni,et al.  Potentials of cell kinetics in the management of patients with ovarian cancers. , 1992, European journal of cancer.

[11]  M. Kattan,et al.  Assessment of the biologic markers p53, ki‐67, and apoptotic index as predictive indicators of prostate carcinoma recurrence after surgery , 1998 .

[12]  K. Hande,et al.  The importance of drug scheduling in cancer chemotherapy: etoposide as an example. , 1996, Stem cells.

[13]  J. Leith,et al.  Host response in tumor growth and progression. , 1996, Invasion & metastasis.

[14]  F. Sinicrope,et al.  Apoptotic and mitotic indices predict survival rates in lymph node-negative colon carcinomas. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[15]  H. Deeg,et al.  HLA-DR-triggered inhibition of hemopoiesis involves Fas/Fas ligand interactions and is prevented by c-kit ligand. , 1997, Journal of immunology.

[16]  P. Lipponen Apoptosis in breast cancer: relationship with other pathological parameters. , 1999, Endocrine-related cancer.

[17]  J. Coindre,et al.  Primary chemotherapy in breast invasive carcinoma: predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2 and GST pi. , 1996, British Journal of Cancer.

[18]  H. Skipper,et al.  Experimental evaluation of potential anticancer agents. XXI. Scheduling of arabinosylcytosine to take advantage of its S-phase specificity against leukemia cells. , 1967, Cancer chemotherapy reports.

[19]  J. Thompson,et al.  Mathematical Model For Human Myeloma Relating Growth Kinetics and Drug Resistance , 1986, Cell and tissue kinetics.

[20]  U. Veronesi,et al.  Changes in biological markers after primary chemotherapy for breast cancers , 1995, International journal of cancer.

[21]  R T Schimke,et al.  Gene amplification, drug resistance, and cancer. , 1984, Cancer research.

[22]  J N Weinstein,et al.  Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. , 1997, Cancer research.

[23]  S. George,et al.  Combination chemotherapy and adriamycin in patients with advanced breast cancer. A Southwest Oncology Group study , 1976, Cancer.

[24]  W R Greco,et al.  Modeling of the time-dependency of in vitro drug cytotoxicity and resistance. , 1998, Cancer research.

[25]  Goldie Jh,et al.  Impact of dose-intense chemotherapy on the development of permanent drug resistance. , 1987 .

[26]  G. Hortobagyi,et al.  Evaluation of high-dose versus standard FAC chemotherapy for advanced breast cancer in protected environment units: a prospective randomized study. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  C. Karapetis,et al.  Matrix Metalloproteinase Inhibitors: Applications in Oncology , 2004, Investigational New Drugs.

[28]  J. Meyer Measurements of Cellular Proliferation and DNA in Breast Carcinoma , 1989 .

[29]  T. Graeber,et al.  Selection of human cervical epithelial cells that possess reduced apoptotic potential to low-oxygen conditions. , 1997, Cancer research.

[30]  L. A. Price Safer cancer chemotherapy using a kinetically-based experimental approach: higher dose intensity with reduced toxicity. , 1987, Cancer treatment reviews.

[31]  H. Mouridsen,et al.  Doxorubicin versus methotrexate both combined with cyclophosphamide, 5-fluorouracil and tamoxifen in postmenopausal patients with advanced breast cancer--a randomised study with more than 10 years follow-up from the Danish Breast Cancer Cooperative Group. Danish Breast Cancer Cooperative Group (DBCG , 1999, European journal of cancer.

[32]  J. Carey DEMOGRAPHY AND POPULATION DYNAMICS OF THE MEDITERRANEAN FRUIT FLY , 1982 .

[33]  K. Alitalo Amplification of cellular oncogenes in cancer cells. , 1985, Medical biology.

[34]  F Pozza,et al.  Breast cancer cell kinetics: immunocytochemical determination of growth fractions by monoclonal antibody Ki-67 and correlation with flow cytometric S-phase and with some features of tumor aggressiveness. , 1991, Anticancer research.

[35]  M Gyllenberg,et al.  Quiescence as an explanation of Gompertzian tumor growth. , 1989, Growth, development, and aging : GDA.

[36]  V. Jordan,et al.  Endocrine pharmacology of antiestrogens as antitumor agents. , 1990, Endocrine reviews.

[37]  M. Province,et al.  Proliferative rate by S‐phase measurement may affect cure of breast carcinoma , 1995, Cancer.

[38]  M. Goldenberg Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. , 1999, Clinical therapeutics.

[39]  G. Bevilacqua,et al.  Primary chemotherapy in locally advanced breast cancer (LABC): effects on tumour proliferative activity, bcl-2 expression and the relationship between tumour regression and biological markers. , 1998, European journal of cancer.

[40]  B. Tibken,et al.  Chapter 7: Biomathematical engineering of cell renewal systems: An approach to a biomathematical model of lymphocytopoiesis , 1995, Stem cells.

[41]  S N Gardner,et al.  A mechanistic, predictive model of dose-response curves for cell cycle phase-specific and -nonspecific drugs. , 2000, Cancer research.

[42]  G. Gudauskas,et al.  5-FU infusion in advanced colorectal cancer: a comparison of three dose schedules. , 1985, Cancer treatment reports.

[43]  L. Norton,et al.  The Norton-Simon hypothesis revisited. , 1986, Cancer treatment reports.

[44]  J. Ragaz,et al.  High-Risk Breast Cancer , 1989, Springer Berlin Heidelberg.

[45]  D Tripathy,et al.  Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  James H. Goldie,et al.  Drug Resistance in Cancer: Mechanisms and Models , 1998 .

[47]  Mike Clarke,et al.  Polychemotherapy for early breast cancer: an overview of the randomised trials , 1998, The Lancet.

[48]  B. Stenkvist,et al.  Appearance of amplified thymidylate synthase or dihydrofolate reductase genes in stage‐IV breast‐cancer patients receiving endocrine treatment , 1993, International journal of cancer.

[49]  R. Greenberg,et al.  Geometry, growth rates, and duration of cancer and carcinoma in situ of the breast before detection by screening. , 1986, Cancer research.

[50]  R. Silvestrini,et al.  Cell kinetics and response to primary intra-arterial chemotherapy in patients with advanced oral cavity tumors. , 1991, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.

[51]  C. Townsend,et al.  Treatment-induced changes in sensitivity in a multiclonal human tumor mixture model in vitro. , 1988, Cancer research.

[52]  J. Panetta,et al.  A mathematical model of drug resistance: heterogeneous tumors. , 1998, Mathematical biosciences.

[53]  J. Bertino,et al.  Fluorouracil in colorectal cancer--a tale of two drugs: implications for biochemical modulation. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  L. Norton,et al.  Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. , 1994, The New England journal of medicine.

[55]  R. Day,et al.  Treatment sequencing, asymmetry, and uncertainty: protocol strategies for combination chemotherapy. , 1986, Cancer research.

[56]  S Gallivan,et al.  A mathematical model of the development of drug resistance to cancer chemotherapy. , 1987, European journal of cancer & clinical oncology.

[57]  K. Jabboury,et al.  Cell proliferation kinetics of normal and tumour tissue in vitro: quiescent reproductive cells and the cycling reproductive fraction , 1995, Cell proliferation.

[58]  F. Goldstein,et al.  Consequences of increasing resistance to antimicrobial agents. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[59]  J S Spratt,et al.  Decelerating growth and human breast cancer , 1993, Cancer.

[60]  Z Bajzer,et al.  Analysis of growth of multicellular tumour spheroids by mathematical models , 1994, Cell proliferation.

[61]  L. Putten,et al.  ARE CELL KINETIC DATA RELEVANT FOR THE DESIGN OF TUMOUR CHEMOTHERAPY SCHEDULES? * , 1974 .

[62]  L. Norton A Gompertzian model of human breast cancer growth. , 1988, Cancer research.

[63]  Z. Agur,et al.  The dynamics of gene amplification described as a multitype compartmental model and as a branching process. , 1991, Mathematical biosciences.

[64]  K. Ang,et al.  Heterogeneity in the development of apoptosis in irradiated murine tumours of different histologies. , 1993, International journal of radiation biology.

[65]  I. Tannock,et al.  Cell kinetics and chemotherapy: a critical review. , 1978, Cancer treatment reports.

[66]  A. Goldhirsch,et al.  Prediction of response to primary chemotherapy for operable breast cancer. , 1999, European journal of cancer.

[67]  C. Hudis,et al.  Rapid administration of multiple cycles of high-dose myelosuppressive chemotherapy in patients with metastatic breast cancer. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[68]  H M Byrne,et al.  Growth of nonnecrotic tumors in the presence and absence of inhibitors. , 1995, Mathematical biosciences.

[69]  T. Kitamura,et al.  Correlation between proliferation, apoptosis, and angiogenesis in prostate carcinoma and their relation to androgen ablation , 1999, Cancer.

[70]  J. Leith,et al.  Changes in the extents of viable and necrotic tissue, interstitial fluid pressure, and proliferation kinetics in clone A human colon tumour xenografts as a function of tumour size , 1994 .

[71]  M. Brizzi,et al.  Cytotoxic and antiproliferative activity of the CMF regimen administered in association with tamoxifen as primary chemotherapy in breast cancer patients. , 1998, International journal of oncology.

[72]  Hryniuk Wm Average relative dose intensity and the impact on design of clinical trials. , 1987, Seminars in oncology.

[73]  M. Retsky,et al.  A stochastic numerical model of breast cancer growth that simulates clinical data. , 1984, Cancer research.

[74]  S. Michelson Mathematical models for multidrug resistance and its reversal , 2004, Cytotechnology.

[75]  S. Gardner Scheduling Chemotherapy: Catch 22 between Cell Kill and Resistance Evolution , 2000 .

[76]  R. P. Falcão,et al.  Increased apoptotic cells in bone marrow biopsies from patients with aplastic anaemia , 1997, British journal of haematology.

[77]  M. Daidone,et al.  Cell proliferation in 3,800 node‐negative breast cancers: Concistency over time of biological and clinical information provided by 3H‐Thymidine labelling index , 1997, International journal of cancer.

[78]  L. Norton,et al.  Tumor size, sensitivity to therapy, and design of treatment schedules. , 1977, Cancer treatment reports.

[79]  P. Rougier,et al.  Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[80]  Marc Mangel,et al.  A revolving dose strategy to delay the evolution of both quantitative vs major monogene resistances to pesticides and drugs , 1998 .